Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome
- 614 Downloads
The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-β2 glycoprotein-I (β2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.
KeywordsAPS Thrombosis Pregnancy morbidity aPL
Compliance with ethical standards
Conflict of interest
The Authors declare that they have no conflict of interest.
Statement of human and animal rights
- 3.Radin M, Cecchi I, Roccatello D et al (2016) Prevalence and thrombotic risk assessment of anti-domain I beta 2 glycoprotein I antibodies: a systematic review and a meta-analysis. Lupus 25 (abstract supplement 1S)Google Scholar
- 4.Sciascia S, Khamashta MA, Bertolaccini ML (2014) New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep 16(5)Google Scholar
- 7.Groot PGDE, Lutters B, Derksen RHWM, Lisman T (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. 1993–1997Google Scholar
- 12.Sciascia S, Khamashta MA, D’Cruz DP (2014) Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol 26(3):269–275Google Scholar
- 15.Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR et al (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3(9):e426–e436CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Sciascia S, Giachino O, Roccatello D Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 30(3):409–413Google Scholar
- 19.Durcan L, Fu W, Petri M (2016) Hypocomplementemia associates with thrombosis in SLE patients with antiphospholipid antibodies. Ann Rheum Dis 75(Suppl2):126Google Scholar
- 20.Pengo V, Ruffatti A, Legnani C et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8(2):237–242Google Scholar